Arima Genomics

Arima Genomics, founded in 2015 and based in San Diego, is a leader in 3D genomics, commercializing a robust Hi-C technology platform. The company operates a dual business model, providing research tools and services while also offering a CLIA-certified clinical diagnostic test (Aventa) for detecting gene fusions and rearrangements in cancer. With a recent $22 million Series C financing and partnerships with companies like Velsera, Arima is positioned to expand the adoption of its structural genomics approach in both research and clinical markets.

Proprietary Hi-C (High-throughput Chromosome Conformation Capture) technology, a proximity ligation method that captures the 3D organizational structure of chromatin to provide integrated sequence and structural genomic data.

Arima competes with other 3D genomics specialists (e.g., Dovetail Genomics, now part of Cantata Bio), large NGS companies like Illumina and PacBio for structural variant analysis, and numerous clinical diagnostic labs offering NGS-based oncology panels. Its differentiation lies in the comprehensiveness of its Hi-C-based structural detection.